CHRS
Coherus BioSciences Inc
1.10$
-3.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +22.7% | -97.5% | +2,715.4% | +8.9% | -23.5% | -86.0% | +34.9% | +12.8% | +10.2% | -3.4% | +16.2% | – | |
| – | +158.6% | -98.3% | +1,953.9% | -29.8% | +63.2% | -89.1% | +19.2% | +6.3% | +5.4% | -5.0% | -9.6% | – | |
| – | -83.4% | -87.5% | +3,976.4% | +41.2% | -59.5% | -80.8% | +49.8% | +17.8% | +13.4% | -2.5% | +32.2% | – | |
| – | +2.8% | +7.8% | -26.9% | +4.4% | -2.0% | +9.8% | +8.5% | +3.9% | +14.4% | -31.3% | +3.8% | – | |
| – | -23.9% | +54.1% | -37.8% | -1.2% | -31.8% | +9.8% | +0.1% | -4.3% | -5.3% | -2.1% | -9.3% | – | |
| – | +2.7% | -9.5% | -18.5% | +0.9% | +10.8% | -21.1% | +4.0% | -4.3% | +9.3% | -18.5% | -3.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3.4% | +4.7% | -52.0% | +0.5% | -0.3% | -59.8% | +5.9% | +2.1% | -3.3% | -2.8% | +6.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -3,836.0% | – | – | – | -1,013.5% | – | |
| – | – | – | -112.6% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.